Jacob Soumerai is an Oncology physician affiliated with Massachusetts General Hospital. OpenAlex indexes 188 publications with 4,093 citations (h-index 26); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
Telephone
617-726-2865Registry record last updated 5 Oct 2017.
Clinical trials
- Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Sponsor: Massachusetts General Hospital
- Biomarker for Infection Risk in CLL and MM
Sponsor: Massachusetts General Hospital
- Zandelisib + Tazemetostat in R/R Follicular Lymphoma
Sponsor: Jacob Soumerai, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Grifols Shared Services North America, Inc.Program year20251 payment
- BeOne Medicines USA, Inc.Program year20257 payments
- F. Hoffmann-La Roche AGProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
- Predictive markers for personalized therapy in chronic lymphocytic leukemia
Massachusetts General Hospital
FY2026$285,931K08CA270202 - Predictive markers for personalized therapy in chronic lymphocytic leukemia
Massachusetts General Hospital
FY2025$285,931K08CA270202 - Predictive markers for personalized therapy in chronic lymphocytic leukemia
Massachusetts General Hospital
FY2024$285,931K08CA270202
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”